
Alphyn Biologics develops proprietary plant-based drug therapies for treating deadly skin diseases, including MRSA infections.
Alphyn Biologics is a life science company dedicated to developing proprietary plant-based drug therapies for treating severe skin diseases, including infections caused by drug-resistant MRSA bacteria. Utilizing their Multi-Target Therapeutic (MTT) technology platform, Alphyn aims to address significant unmet medical needs in dermatology. Their market focus includes conditions like atopic dermatitis, leveraging innovative plant-derived solutions to offer effective treatments.
Alphyn Biologics has achieved significant milestones, including positive results from the second cohort of their Phase 2a clinical trial in atopic dermatitis. They have also presented interim results from their first human phase trial of Zabalafin (AB-101a) at the Masters of Pediatric Dermatology Symposium. These advancements underscore Alphyn's commitment to pioneering new therapies in dermatology, positioning them as a key player in the field of skin disease treatment.

Alphina Therapeutics

DermBiont
dermbiont.com

Aldena Therapeutics

Asalyxa Bio

EpiBiologics
epibiologics.com

MatriSys Bioscience
matrisysbio.com

Naked Biome

TBT Pharma
tbtpharma.com

Amplifica
amplificabio.com

Alveolus Bio
alveolusbio.com

Santa Ana Bio
santaanabio.com

Atavistik Bio
atavistikbio.com

Arcutis Biotherapeutics
arcutis.com

Timber Pharmaceuticals

Algen Biotechnologies
algenbio.com
Companies similar to Alphyn Biologics include Alphina Therapeutics, DermBiont, Aldena Therapeutics and Asalyxa Bio.
Alphyn Biologics was founded in 2019.
Alphyn Biologics' headquarters is located in Cincinnati, OH, US.
Alphyn Biologics' most recent funding round was for $3.3M (USD) in September 2022.
As of Sep 15, 2022, Alphyn Biologics has raised a total of $5.5M (USD).
Alphyn Biologics has 2 employees as of Feb 5, 2024.